News blog
Medgenics Inc
- BY: Andrew Hore |
- POSTED: 31/08/2009 |
Medgenics Inc says that one patient has lasted nearly 11 months on one EPODURE treatment and this is helping the company to advance its discussions with pharma companies.
Israel-based Medgenics is a biopharmaceutical company, which has developed a technology that could replace regular injections as a treatment for various ailments. The first product is called EPODURE, because it produces EPO (erythro-protein) to treat anaemia.
The 72 year old patient has previously needed regular EPO injections. Many patients need three injections each week. Most of the other patients in the clinical trial have also gone longer than normal without injections. The trials need to be expanded to a broader range of patients to further prove the efficacy of the treatment.
Medgenics is in talks with a major pharma company to co-develop a treatment producing Factor VIII protein for treating haemophilia, a market worth more than $3.5bn a year. An Asian biopharma company is interested in doing a deal that would involve treatments for Asian markets and an investment in Medgenics.
Medgenics has won a $1.3m grant from the Israel government.
At 7.125p a share, Medgenics is valued at £8.73m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|